13F Filings for MPM BIOIMPACT LLC (CIK: 1687078)
View the most recent portfolio holdings disclosed by MPM BIOIMPACT LLC in their 13F filing.
| Holding | Shares | Value | Portfolio Percent | Change Status | Change Amount |
|---|---|---|---|---|---|
| CGEM - Cullinan Therapeutics, Inc.(Class: Common) | 7.65M | $57.59M | 9.98% | Unchanged | |
| MDGL - Madrigal Pharmaceuticals Inc(Class: Common) | 100.42K | $30.39M | 5.27% | Unchanged | |
| ZLAB - Zai Lab Ltd(Class: ADR) | 745.06K | $26.05M | 4.51% | Decreased | 88.60K (10.0%, $4.07M) |
| GH - Guardant Health Inc(Class: Common) | 442.66K | $23.04M | 3.99% | Unchanged | |
| SPRY - ARS Pharmaceuticals Inc(Class: Common) | 1.30M | $22.74M | 3.94% | Decreased | 9.71K (0.0%, $6.23M) |
| EWTX - Edgewise Therapeutics Inc(Class: Common) | 1.72M | $22.56M | 3.91% | Increased | 615.30K (55.0%, $1.76M) |
| RNA - Avidity Biosciences Inc(Class: Common) | 760.02K | $21.58M | 3.74% | Increased | 45.80K (6.0%, $500.73K) |
| PTCT - PTC Therapeutics Inc(Class: Common) | 438.48K | $21.42M | 3.71% | Decreased | 1.50K (0.0%, $1.01M) |
| TRVI - Trevi Therapeutics Inc(Class: Common) | 3.41M | $18.64M | 3.23% | Decreased | 21.41K (0.0%, $2.93M) |
| ORIC - Oric Pharmaceuticals Inc(Class: Common) | 1.73M | $17.55M | 3.04% | Increased | 329.86K (23.0%, $9.74M) |
| NTRA - Natera Inc(Class: Common) | 98.92K | $16.71M | 2.90% | Decreased | 58.12K (37.0%, $5.50M) |
| ALKS - Alkermes Plc(Class: Common) | 549.26K | $15.71M | 2.72% | Increased | 211.66K (62.0%, $4.57M) |
| MLTX - Moonlake Immunotherapeutics(Class: Class A Ord) | 313.57K | $14.80M | 2.56% | Decreased | 2.48K (0.0%, $2.45M) |
| MBX - MBX Biosciences Inc(Class: Common) | 1.29M | $14.77M | 2.56% | Increased | 161.47K (14.0%, $6.41M) |
| CMPX - Compass Therapeutics, Inc.(Class: Common) | 5.62M | $14.62M | 2.53% | Decreased | 2.82M (33.0%, $1.42M) |
| RARE - Ultragenyx Pharmaceutical Inc(Class: Common) | 395.70K | $14.39M | 2.49% | Decreased | 2.75K (0.0%, $40.04K) |
| JANX - Janux Therapeutics Inc(Class: Common) | 614.28K | $14.19M | 2.46% | Increased | 47.09K (8.0%, $1.12M) |
| TARS - Tarsus Pharmaceuticals Inc(Class: Common) | 341.50K | $13.83M | 2.40% | New | 341.50K ($13.83M) |
| DYN - Dyne Therapeutics, Inc.(Class: Common) | 1.45M | $13.77M | 2.39% | New | 1.45M ($13.77M) |
| VERA - Vera Therapeutics Inc.(Class: Class A Ord) | 563.08K | $13.27M | 2.30% | Increased | 147.36K (35.0%, $3.28M) |
| CRNX - Crinetics Pharmaceuticals Inc.(Class: Common) | 428.98K | $12.34M | 2.14% | Decreased | 202.99K (32.0%, $8.86M) |
| RVMD - Revolution Medicines, Inc.(Class: Common) | 315.72K | $11.62M | 2.01% | Decreased | 1.36K (0.0%, $403.36K) |
| AKBA - Akebia Therapeutics Inc(Class: Common) | 2.89M | $10.52M | 1.82% | New | 2.89M ($10.52M) |
| OLMA - Olema Pharmaceuticals, Inc.(Class: Common) | 2.38M | $10.13M | 1.76% | Decreased | 551.68K (18.0%, $884.95K) |
| XENE - Xenon Pharmaceuticals Inc(Class: Common) | 323.40K | $10.12M | 1.75% | Increased | 20K (6.0%, $56.65K) |